These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 18536235)

  • 21. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
    Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
    J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New and emerging treatment of chronic hepatitis B.
    Keeffe EB; Marcellin P
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):285-94. PubMed ID: 17218162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
    Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Management of chronic hepatitis B].
    von Weizsäcker F
    Praxis (Bern 1994); 2005 Apr; 94(16):649-52. PubMed ID: 15900829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    Wang JC; He LL; Chen Q
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
    Kang SH; Yim HJ; Kim HR; Kang K; Suh SJ; Lee HJ; Yoon EL; Kim JH; Seo YS; Yeon JE; Byun KS
    J Clin Gastroenterol; 2014; 48(10):889-95. PubMed ID: 24440937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon.
    Marcellin P; Sung J; Piratvisuth T
    Liver Int; 2010 May; 30(5):657-68. PubMed ID: 20158610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future.
    Férir G; Kaptein S; Neyts J; De Clercq E
    Rev Med Virol; 2008; 18(1):19-34. PubMed ID: 17966115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal duration of therapy in HBV-related cirrhosis.
    Lim CY; Kowdley KV
    J Antimicrob Chemother; 2007 Jul; 60(1):2-6. PubMed ID: 17483546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current trends in chronic hepatitis B management: results of a questionnaire.
    Les I; García-Martínez R; Córdoba J; Quintana M; Esteban R; Buti M
    Eur J Gastroenterol Hepatol; 2009 Oct; 21(10):1177-83. PubMed ID: 19430301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic recommendations for year 2010: antiviral treatment of chronic HBV infection].
    Juszczyk J; Boroń-Kaczmarska A; Cianciara J; Flisiak R; Gładysz A; Halota W; Kryczka W; Małkowski P; Pawłowska M; Simon K;
    Przegl Epidemiol; 2010; 64(1):81-2. PubMed ID: 20499665
    [No Abstract]   [Full Text] [Related]  

  • 38. Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
    Sherman M; Lee SS
    Can J Gastroenterol; 2011 Oct; 25(10):538-41. PubMed ID: 22059156
    [No Abstract]   [Full Text] [Related]  

  • 39. [Chronic hepatitis B: which patients should be treated and how?].
    Asselah T; Ripault MP; Marcellin P
    Gastroenterol Clin Biol; 2005 Apr; 29(4):374-83. PubMed ID: 15864198
    [No Abstract]   [Full Text] [Related]  

  • 40. WHO survey finds half of countries do not have clinical guidelines for treating hepatitis.
    Gulland A
    BMJ; 2013 Jul; 347():f4715. PubMed ID: 23884975
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.